CrystalGenomics, Inc.
18
1
1
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.6%
1 terminated/withdrawn out of 18 trials
92.3%
+5.8% vs industry average
6%
1 trials in Phase 3/4
33%
4 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649
Role: lead
Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome
Role: lead
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Role: lead
Phase III Study of CG100649 in Osteoarthritis Patients
Role: lead
Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
Role: lead
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Role: lead
Drug-Drug Interaction Study of "CG-651" in Healthy Volunteer
Role: lead
Drug-Drug Interaction Study of "CG100650" in Healthy Volunteers
Role: lead
CG-549 Tablet Pharmacokinetics Study
Role: lead
CG400549 Single Ascending Dose Study
Role: lead
Pharmacokinetics and Safety of 'CG-745 IV' and 'CG-750' in Healthy Male Adults
Role: lead
Study to Compare Safety and Pharmacokinetics of "CG1801" and "CGL1802" in Healthy Volunteers
Role: lead
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Role: lead
Phase I Study on Multiple Oral Dosing of CG100649
Role: lead
Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition
Role: collaborator
Multiple Ascending Doses Study of CG400549
Role: lead
Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile
Role: lead
Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects
Role: lead
All 18 trials loaded